Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: A history and discussion of future rational use

Therapeutic Advances in Hematology

Volumn 3, Issue 6, 2012, Pages 375-389

  Warner, Jeremy L ^a   Arnason, Jon E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

agammaglobulinaemia tyrosine kinase; alemtuzumab; B cell; CD52 antigen; chronic; leukemia; lymphocytic; phosphatidylinositol 3 kinase; recurrence

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CD52 ANTIGEN; COTRIMOXAZOLE; FAMCICLOVIR; FLUDARABINE; PHOSPHATIDYLINOSITOL 3 KINASE; RITUXIMAB; STEROID;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; HERPES SIMPLEX; HUMAN; INFECTION COMPLICATION; PATIENT MONITORING; PNEUMOCYSTIS JIROVECII INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE;

EID: 84993814502     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712458949     Document Type: Review

References (102)

1. Albo C. Perez-Encinas M. Lavilla E. Dios A. Plaza J. Simiele A. et al. (2007) Incidence and spectrum of infection in patients treated with alemtuzumab: a multicenter experience, 12th Congress of the European Hematology Association. Haematologica 92(Suppl. 1): abstract 1036.
2. Badoux X. Keating M. Wang X. O'Brien S. Ferrajoli A. Faderl S. et al. (2011) Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118: 2085–2093.
3. Bezares R. Stemelin G. Diaz A. Argentieri D. Zubiaur E. Garay G. et al. (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukemia Lymphoma 52: 1936–1941.
4. Bowen A. Zomas A. Emmett E. Matutes E. Dyer M. Catovsky D. (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and b-prolymphocytic leukaemia. British Journal of Haematology 96: 617–619.
5. Brown J. Messmer B. Werner L. Mikler E. Fisher D. Lacasce A. et al. (2010) A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed CLL/SLL, ASH Annual Meeting. Blood 116: abstract 1381.
6. Buggins A. Mufti G. Salisbury J. Codd J. Westwood N. Arno M. et al. (2002) Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 100: 1715–1720.
7. Byrd J. Waselenko J. Keating M. Rai K. Grever M. (2000) Novel therapies for chronic lymphocytic leukemia in the 21st century. Seminars in Oncology 27: 587–597.
8. Cheson B. (1991) New modalities of therapy in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 11: 167–177.
9. Cheson B. (2009) Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7: 263–271.
10. Cheson B. Bennett J. Grever M. Kay N. Keating M. O'Brien S. et al. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990–4997.
11. Cheson B. Bennett J. Rai K. Grever M. Kay N. Schiffer C. et al. (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29: 152–163.
12. Cortelezzi A. Gritti G. Laurenti L. Cuneo A. Ciolli S. Di Renzo N. et al. (2012) An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed / refractory chronic lymphocytic leukaemia patients. Br J Haematol 156: 481–489.
13. Cortelezzi A. Pasquini M. Gardellini A. Gianelli U. Bossi A. Reda G. et al. (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23: 2027–2033.
14. Cortelezzi A. Pasquini M. Sarina B. Bertani G. Grifoni F. Colombi M. et al. (2005) A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica 90: 410–412.
15. de Rooij M. Kuil A. Geest C. Eldering E. Chang B. Buggy J. et al. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119: 2590–2594.
16. Dohner H. Stilgenbauer S. Benner A. Leupolt E. Krober A. Bullinger L. et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910–1916.
17. Dyer M. Hale G. Marcus R. Waldmann H. (1990) Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leukemia Lymphoma 2: 179–193.
18. Egle A. Melchardt T. Pleyer L. Tinhofer I. Lang A. Keil F. et al. (2009) Final results of oral fludarabine with concomitant subcutaneous alemtuzumab in relapse / refractory b-chronic lymphocytic leukaemia (B-CLL): the FLUSALEM study, 14th Congress of the European Hematology Association, Haematologica 94(Suppl. 2): abstract 0353.
19. Egle A. Melchardt T. Weiss L. Steurer M. Greil R. (2010) The BENDALEM CLL 6 AGMT study - bendamustine combined with alemtuzumab in relapsed / refractory chronic lymphocytic leukemia (CLL): results of a planned interim analysis, ASH Annual Meeting, Blood 116: abstract 4633.
20. Elter T. Borchmann P. Schulz H. Reiser M. Trelle S. Schnell R. et al. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23: 7024–7031.
21. Elter T. Gercheva-Kyuchukova L. Pylylpenko H. Robak T. Jaksic B. Rekhtman G. et al. (2011) Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 12: 1204–1213.
22. Elter T. James R. Busch R. Winkler D. Ritgen M. Bottcher S. et al. (2012) Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 15 May (epub ahead of print).
23. Faderl S. Ferrajoli A. Wierda W. O'Brien S. Lerner S. Keating M. (2010) Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116: 2360–2365.
24. Faderl S. Thomas D. O'Brien S. Garcia-Manero G. Kantarjian H. Giles F. et al. (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101: 3413–3415.
25. Ferrajoli A. O'Brien S. Cortes J. Giles F. Thomas D. Faderl S. et al. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98: 773–778.
26. Ferrajoli A. Wierda W. Lapushin R. O'Brien S. Faderl S. Browning M. et al. (2008) Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 80: 296–298.
27. Fiegl M. Erdel M. Tinhofer I. Brychtova Y. Panovska A. Doubek M. et al. (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Annals of Oncology 21: 2410–2419.
28. Fiegl M. Falkner A. Hopfinger G. Brugger S. Zabernigg A. Bauer F. et al. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 107: 2408–2416.
29. Fiegl M. Falkner F. Steurer M. Zojer N. Hopfinger G. Haslbauer F. et al. (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann Hematol 90: 1083–1091.
30. Flowers C. Rosenthal H. Brown J. Stock W. Katzen H. Lakhanpal S. et al. (2007) Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed / refractory B-cell chronic lymphocytic leukemia (CLL), ASH Annual Meeting. Blood 110: abstract 3111.
31. Fruman D. Rommel C. (2011) PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 1: 562–572.
32. Golay J. Manganini M. Rambaldi A. Introna M. (2004) Effect of alemtuzumab on neoplastic b cells. Haematologica 89: 1476–1483.
33. Gribben J. Stephans K. Marshal B. (2005) Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: results from a phase II study. ASH Annual Meeting. Blood 106: abstract 5046.
34. Gritti G. Reda G. Maura F. Piciocchi A. Baldini L. Molica S. et al. (2012) Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Lymphoma 53: 424–429.
35. Hainsworth J. Vazquez E. Spigel D. Raefsky E. Bearden J. Saez R. et al. (2008) Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 112: 1288–1295.
36. Hale G. Bright S. Chumbley G. Hoang T. Metcalf D. Munro A. et al. (1983 a) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62: 873–882.
37. Hale G. Dyer M. Clark M. Phillips J. Marcus R. Riechmann L. et al. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394–1399.
38. Hale G. Rebello P. Brettman L. Fegan C. Kennedy B. Kimby E. et al. (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104: 948–955.
39. Hale G. Swirsky D. Hayhoe F. Waldmann H. (1983 b) Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1: 321–334.
40. Hallek M. (2012) FCA: forget chemoimmunotherapy with alemtuzumab? Blood 119: 5059–5060.
41. Hallek M. Cheson B. Catovsky D. Caligaris-Cappio F. Dighiero G. Dohner H. et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446–5456.
42. Herman S. Gordon A. Hertlein E. Ramanunni A. Zhang X. Jaglowski S. et al. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117: 6287–6296.
43. Hillmen P. Skotnicki A. Robak T. Jaksic B. Dmoszynska A. Wu J. et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25: 5616–5623.
44. Hoellenriegel J. Meadows S. Sivina M. Wierda W. Kantarjian H. Keating M. et al. (2011) The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118: 3603–3612.
45. Hui D. Lam W. Toze C. Delorme M. Noble M. Klimo P. et al. (2008) Alemtuzumab in clinical practice: a British Columbia experience. Leukemia Lymphoma 49: 218–226.
46. Ionita H. Cheveresan L. Inonita I. Cheveresan M. (2009) Alemtuzumab in fludarabine-refractory CLL, 14th Congress of the European Hematology Association. Haematologica 94(Suppl. 2): abstract 1559.
47. Karlsson C. Lundin J. Kimby E. Kennedy B. Moreton P. Hillmen P. et al. (2009) Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 144: 78–85.
48. Kataeva E. Golenkov A. Triphonova E. Buravtsova I. (2009) The alemtuzumab treatment of refractory to fludarabine chronic lymphocytic leukemia patients. ASH Annual Meeting. Blood 114: abstract 4415.
49. Kaufman M. Caramanica A. Janson D. Driscoll N. Johnson C. Kohn N. et al. (2011) Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Med Oncol 28: 532–538.
50. Keating M. (2002) Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554–3561.
51. Kennedy B. (2002) CAMPATH-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245–2247.
52. Lannutti B. Meadows S. Herman S. Kashishian A. Steiner B. Johnson A. et al. (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591–594.
53. Laros-Van Gorkom B. Huisman C. Wijermans P. Schipperus M. (2007) Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 65: 333–338.
54. Laurenti L. Piccioni P. Tarnani M. Efremov D. Fiorini A. Garzia M. et al. (2005) Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Haematologica 90: 1143–1145.
55. Lepretre S. Aurran T. Mahe B. Cazin B. Tournilhac O. Maisonneuve H. et al. (2012) Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119: 5104–5110.
56. Lim S. Davey G. Marcus R. (1993) Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341: 432–433.
57. Lin T. Flinn I. Lucas M. Porcu P. Sickler J. Moran M. et al. (2005) Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 19: 1207–1210.
58. Lozanski G. Heerema N. Flinn I. Smith L. Harbison J. Webb J. et al. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p 53 mutations and deletions. Blood 103: 3278–3281.
59. Lundin J. Kimby E. Bjorkholm M. Broliden P. Celsing F. Hjalmar V. et al. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768–773.
60. Lundin J. Osterborg A. Brittinger G. Crowther D. Dombret H. Engert A. et al. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 16: 3257–3263.
61. Lundin J. Porwit-Macdonald A. Rossmann E. Karlsson C. Edman P. Rezvany M. et al. (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18: 484–490.
62. Majolino I. Ladetto M. Locasciulli A. Drandi D. Benedetti F. Gallamini A. et al. (2006) High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Med Oncol 23: 359–368.
63. Martin S. Marty F. Fiumara K. Treon S. Gribben J. Baden L. (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43: 16–24.
64. Mone A. Cheney C. Banks A. Tridandapani S. Mehter N. Guster S. et al. (2006) Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20: 272–279.
65. Montillo M. Tedeschi A. Petrizzi V. Ricci F. Crugnola M. Spriano M. et al. (2011) An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed / refractory patients with B-cell chronic lymphocytic leukemia. Blood 118: 4079–4085.
66. Montserrat E. Moreno C. Esteve J. Urbano-Ispizua A. Gine E. Bosch F. (2006) How I treat refractory CLL. Blood 107: 1276–1283.
67. Moreau P. Pylypenko H. Grosicki S. Karamanesht I. Leleu X. Grishunina M. et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431–440.
68. Moreton P. Kennedy B. Lucas G. Leach M. Rassam S. Haynes A. et al. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23: 2971–2979.
69. Nabhan C. Patton D. Gordon L. Riley M. Kuzel T. Tallman M. et al. (2004) A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and / or refractory chronic lymphocytic leukemia (CLL). Leukemia Lymphoma 45: 2269–2273.
70. Nuckel H. Frey U. Roth A. Duhrsen U. Siffert W. (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 514: 217–224.
71. O'Brien S. Barrientos J. Flinn I. Barr P. Burger J. Navarro T. et al. (2012) Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed / refractory (r/r) chronic lymphocytic leukemia (CLL): interim results of a phase Ib / II study, ASCO Annual Meeting. J Clin Oncol 30(Suppl.): abstract 6515.
72. O'Brien S. Burger J. Blum K. Furman R. Coutre S. Sharman J. et al. (2011) The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (r/r) chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib / II study, ASH Annual Meeting. Blood 118: abstract 983.
73. O'Brien S. Keating M. Mocarski E. (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7: 125–130.
74. O'Brien S. Ravandi F. Riehl T. Wierda W. Huang X. Tarrand J. et al. (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111: 1816–1819.
75. Osterborg A. Dyer M. Bunjes D. Pangalis G. Bastion Y. Catovsky D. et al. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15: 1567–1574.
76. Osterborg A. Fassas A. Anagnostopoulos A. Dyer M. Catovsky D. Mellstedt H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93: 151–153.
77. Osterborg A. Foa R. Bezares R. Dearden C. Dyer M. Geisler C. et al. (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23: 1980–1988.
78. Osuji N. Del Giudice I. Matutes E. Wotherspoon A. Dearden C. Catovsky D. (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90: 1435–1436.
79. Pettitt A. Jackson R. Carruthers S. Dodd J. Dodd S. Oates M. et al. (2012) Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL 206 trial. J Clin Oncol 30: 1647–1655.
80. Pettitt A. Matutes E. Oscier D. (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p 53 defects. Leukemia 20: 1441–1445.
81. Ponader S. Chen S. Buggy J. Balakrishnan K. Gandhi V. Wierda W. et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119: 1182–1189.
82. Pospisilova S. Gonzalez D. Malcikova J. Trbusek M. Rossi D. Kater A. et al. (2012) ERIC recommendations on TP 53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26: 1458-1461.
83. Rai K. Freter C. Mercier R. Cooper M. Mitchell B. Stadtmauer E. et al. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20: 3891–3897.
84. Rawstron A. Kennedy B. Moreton P. Dickinson A. Cullen M. Richards S. et al. (2004) Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 103: 2027–2031.
85. Rezvany M. Tehrani M. Karlsson C. Lundin J. Rabbani H. Osterborg A. et al. (2006) Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 135: 475–485.
86. Riechmann L. Clark M. Waldmann H. Winter G. (1988) Reshaping human antibodies for therapy. Nature 332: 323–327.
87. Rieger K. von Grunhagen U. Fietz T. Thiel E. Knauf W. (2004) Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia–change of regimen needed? Leukemia Lymphoma 45: 345–349.
88. Siegel R. Ward E. Brawley O. Jemal A. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212–236.
89. Skoetz N. Bauer K. Elter T. Monsef I. Roloff V. Hallek M. et al. (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia (review). Cochrane Database Syst Rev 2: 1–90.
90. Stilgenbauer S. Cymbalista F. Leblond V. Delmer A. Zenz T. Winkler D. et al. (2010) Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-sct in CLL with 17p- or refractory to fludarabine - interim analysis of the CLL2O trial of the GCLLSG and GCGCLL/MW, ASH Annual Meeting. Blood 116: abstract 920.
91. Stilgenbauer S. Dohner H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p 53 gene mutation and resistance to chemotherapy. New Eng J Med 347: 452–453.
92. Stilgenbauer S. Zenz T. Winkler D. Buhler A. Schlenk R. Groner S. et al. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27: 3994–4001.
93. Tedeschi A. Coscia M. Rossi D. Ricci F. D'Arena G. Orlandi E. et al. (2011) Bendamustine and alemtuzumab (Ben Cam) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the Italian trial, 16th Congress of the European Hematology Association. Haematologica 96(Suppl. 2): abstract 0099.
94. Thieblemont C. Bouafia F. Hornez E. Dumontet C. Tartas S. Antal D. et al. (2004) Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma (B-CLL/SLL). Leukemia Lymphoma 45: 711–714.
95. Ursuleac I. Georgescu O. Vasilica M. Niculescu-Mizil E. Stoia R. Badelita S. et al. (2011) Treatment of B-CLL and T cell non-Hodgkin lymphomas patients with alemtuzumab; the experience of a single Romanian center, 16th Congress of the European Hematology Association. Haematologica 96(Suppl. 2): abstract 1189.
96. Vallejo C. Rios E. de La Serna J. Jarque I. Ferra C. Sanchez-Godoy P. et al. (2011) Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Exp Rev Hematol 4: 9–16.
97. Varghese A. Sayala H. Moreton P. Jones R. Rawstron A. Sheila J. et al. (2010) Long term survival report of the UKCLL 02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group), ASH Annual Meeting. Blood 116: abstract 922.
98. Xia M. Hale G. Lifely M. Ferguson M. Campbell D. Packman L. et al. (1993) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 293: 633–640.
99. Xia M. Hale G. Waldmann H. (1993) Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 30: 1089–1096.
100. Xia M. Tone M. Packman L. Hale G. Waldmann H. (1991) Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21: 1677–1684.
101. Zagoskina P. Zotina E. Grishina I. Demyanova V. (2011) Monoclonal anti-CD52 antibody treatment in chronic lymphocytic leukemia patients that are refractory to fludarabine-containing chemotherapy regimens, 16th Congress of the European Hematology Association. Haematologica 96(Suppl. 2): abstract 1186.
102. Zent C. Laplant B. Link B. Call T. Shanafelt T. Bowen D. et al. (2011) Pentostatin, alemtuzumab, and low dose rituximab is effective therapy for relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL), ASH Annual Meeting. Blood 118: abstract 1790.